Oculis Holding AG (OCS) Other financing activities (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Other financing activities came in at $614239.3 in Q1 2026, up 75.88% year-on-year from $349246.7 in Q1 2025, and up 102.03% quarter-over-quarter from $304034.3 in Q4 2025.
Oculis Holding AG (OCS) Other financing activities (2022 - 2026) Analysis & Trends
Oculis Holding AG's Other financing activities history runs 5 years deep, the most recent figure standing at $614239.3 for Q1 2026.
- On a quarterly basis, Other financing activities rose 75.88% year-over-year to $614239.3 in Q1 2026; TTM through Mar 2026 was $2.5 million, a 117.07% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, up 114.48% from the prior year.
- Other financing activities rose to $614239.3 in Q1 2026 per OCS's latest filing, from $304034.3 in the prior quarter.
- Across five years, Other financing activities topped out at $1.6 million in Q2 2025 and bottomed at -$398517.7 in Q3 2023.
- The 5-year median for Other financing activities is $203867.5 (2023), against an average of $310164.4.
- Biggest YoY gain for Other financing activities was 3929.48% in 2025; the steepest drop was 98.02% in 2025.
- Year by year, Other financing activities stood at $8304.2 in 2022, then soared by 1692.0% to $148810.8 in 2023, then tumbled by 42.47% to $85614.1 in 2024, then surged by 255.12% to $304034.3 in 2025, then surged by 102.03% to $614239.3 in 2026.
- Per Business Quant, the three latest OCS Other financing activities figures stand at $614239.3 (Q1 2026), $304034.3 (Q4 2025), and $13751.2 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 614,239.25 |
| Mar 31, 2026 | 614,239.25 |
| Dec 31, 2025 | 304,034.26 |
| Dec 31, 2025 | 304,034.26 |
| Sep 30, 2025 | 13,751.20 |
| Sep 30, 2025 | 13,751.20 |
| Jun 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Mar 31, 2025 | 349,246.67 |
| Mar 31, 2025 | 349,246.67 |
| Dec 31, 2024 | 85,614.14 |
| Dec 31, 2024 | 85,614.14 |
| Sep 30, 2024 | 693,678.55 |
| Sep 30, 2024 | 693,678.55 |
| Jun 30, 2024 | 39,808.57 |
| Jun 30, 2024 | 39,808.57 |
| Mar 31, 2024 | 258,924.20 |
| Mar 31, 2024 | 258,924.20 |
| Dec 31, 2023 | 148,810.79 |
| Dec 31, 2023 | 148,810.79 |